These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20978502)

  • 1. Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
    Al-Batran SE; Güntner M; Pauligk C; Scholz M; Chen R; Beiss B; Stopatschinskaja S; Lerbs W; Harbeck N; Jäger E
    Br J Cancer; 2010 Nov; 103(10):1518-23. PubMed ID: 20978502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.
    Al-Batran SE; Bischoff J; von Minckwitz G; Atmaca A; Kleeberg U; Meuthen I; Morack G; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Br J Cancer; 2006 Jun; 94(11):1615-20. PubMed ID: 16685267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center.
    Khallaf SM; Roshdy J; Ibrahim A
    J Egypt Natl Canc Inst; 2020 Apr; 32(1):20. PubMed ID: 32372114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer.
    Chow LW; Yip AY; Lang BH
    Am J Clin Oncol; 2007 Apr; 30(2):133-8. PubMed ID: 17414461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.
    Livi L; Meattini I; Scotti V; De Luca Cardillo C; Galardi A; Iermano C; Sanchez L; Nori J; Mangoni M; Franzese C; Orzalesi L; Bertocci S; Agresti B; Masoni T; Bianchi S; Cataliotti L; Biti G
    J Chemother; 2011 Jun; 23(3):158-62. PubMed ID: 21742585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated liposomal doxorubicin (Duomeisu
    Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
    Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
    Verma S; Dent S; Chow BJ; Rayson D; Safra T
    Cancer Treat Rev; 2008 Aug; 34(5):391-406. PubMed ID: 18358614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
    Harbeck N; Saupe S; Jäger E; Schmidt M; Kreienberg R; Müller L; Otremba BJ; Waldenmaier D; Dorn J; Warm M; Scholz M; Untch M; de Wit M; Barinoff J; Lück HJ; Harter P; Augustin D; Harnett P; Beckmann MW; Al-Batran SE;
    Breast Cancer Res Treat; 2017 Jan; 161(1):63-72. PubMed ID: 27798749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
    Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
    Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
    Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
    J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.
    Fiegl M; Mlineritsch B; Hubalek M; Bartsch R; Pluschnig U; Steger GG
    BMC Cancer; 2011 Aug; 11():373. PubMed ID: 21864402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.
    Palmieri C; Misra V; Januszewski A; Yosef H; Ashford R; Keary I; Davidson N
    Clin Breast Cancer; 2014 Apr; 14(2):85-93. PubMed ID: 24325950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.
    Vassilomanolakis M; Koumakis G; Barbounis V; Demiri M; Pateras H; Efremidis AP
    Ann Oncol; 2000 Sep; 11(9):1155-60. PubMed ID: 11061611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.
    Huober J; Fett W; Nusch A; Neise M; Schmidt M; Wischnik A; Gerhardt S; Goehler T; Lück HJ; Rost A
    BMC Cancer; 2010 Jan; 10():2. PubMed ID: 20047698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
    Vici P; Colucci G; Giotta F; Sergi D; Filippelli G; Perri P; Botti C; Vizza E; Carpino A; Pizzuti L; Latorre A; Giannarelli D; Lopez M; Di Lauro L
    J Exp Clin Cancer Res; 2011 Apr; 30(1):39. PubMed ID: 21481280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
    O'Brien ME
    Anticancer Drugs; 2008 Jan; 19(1):1-7. PubMed ID: 18043124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
    Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
    Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
    Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
    Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.